As part of our series focussing on medicines available in Australia, this review outlines the bowel cleansing efficacy and tolerability profile of NER1006, supported by evidence from real-world studies, and its use in a range of patient groups, including older adults, and patients with diabetes, obesity, or renal insufficiency.
Guiding commentary has been provided by Associate Professor Jonathan Segal, an academic Gastroenterologist, Melbourne, Australia.
Please login below to download this issue (PDF)